Luvis

Quick links to important sections

Luvis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Luvis

Property Description
Active Ingredient Hypromellose (HPMC)
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class Ophthalmic Lubricant (Artificial Tears)
Common Use Relief of dryness and irritation
Origin Semisynthetic Polymer

What is Luvis and What Type of Medicine is It?

Luvis is a pharmaceutical product formulated as an ophthalmic solution (eye drops) designed for topical ocular administration. It is classified as an ophthalmic lubricant, a high-level category of products commonly known as artificial tears that primarily function as a tear substitute.

The classification of Hypromellose as an eye lubricant is clinically recognized globally. This confirms that the medicine is fundamentally intended to physically supplement the natural tear film, supporting the eye's moisture levels. Luvis is typically positioned as an over-the-counter (OTC) treatment, differentiating it from prescription-only drops that may contain complex chemical agents.


Composition: What is Hypromellose and Its Origin?

The sole therapeutic agent in Luvis is the active ingredient, Hypromellose, which is the official common name (INN) for Hydroxypropyl methylcellulose (HPMC). This compound is a semisynthetic polymer derived from natural cellulose, resulting in a controlled-viscosity substance optimized for ophthalmic application.

The final preparation is a sterile, buffered aqueous solution (water-based vehicle). Hypromellose is considered a pharmacologically inert substance because it lacks direct systemic drug-like effects, serving instead as a viscosity-enhancing agent to improve the solution’s adherence to the eye. This inert profile is suitable for providing chronic, simple symptomatic relief.


General Purpose: Why is Luvis Used?

The product's essential purpose is to furnish the eye with sustained moisture and a protective physical barrier. By facilitating continuous lubrication and surface hydration, Luvis assists in relieving the symptomatic discomforts associated with dry eye conditions.

Its primary mechanism focuses on tear film stabilization, where the solution helps prevent the premature evaporation of the natural tear layer. Pharmacological studies have confirmed the efficacy of HPMC in supporting ocular surface hydration over time. This action translates directly into relief from common symptoms such as a foreign body sensation, grittiness, or burning.

Regulatory References

  1. Hypromellose (Ophthalmic) Drug Label - NIH DailyMed

What side effects are possible with Luvis?

Possible side effects and safety information

The safety profile of Luvis (Hypromellose ophthalmic solution) is primarily defined by local, ocular adverse reactions, which is consistent with its intended use as a topical, non-systemically absorbed ophthalmic lubricant. Regulatory documents classify the observed effects mainly under Eye Disorders.


Adverse Reaction Scope and Frequency

Adverse reactions associated with the use of ophthalmic solutions containing Hypromellose are typically mild and localized. These effects are often characterized in official labeling by their transient nature, meaning they are short-lived, particularly those occurring immediately upon instillation.

Category Documented Effects
Common / Not Known Transient blurred vision, mild stinging or burning sensation, ocular discomfort, eye redness (ocular hyperaemia).
Rare Hypersensitivity or allergic reactions.

Safety Considerations and Restrictions

Serious Adverse Reactions for this class are limited to potentially severe Hypersensitivity reactions to the active ingredient or excipients, which are rare events that represent the highest tier of non-local safety concern.

Regulatory labels include important safety restrictions related to the excipient composition. If the product contains a common preservative like Benzalkonium Chloride, it is contraindicated for use while wearing soft contact lenses, as the preservative may accumulate. Due to the potential for transient blurring, official documents advise against operating hazardous machinery or driving until vision is clear. No specific safety adjustments are typically noted for older adults or in cases of renal or hepatic impairment due to the negligible systemic exposure of the polymer.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory labeling for Luvis (Hypromellose ophthalmic solution) provides specific information on overdose, which is defined by the product’s core properties and subsequent lack of expected toxicity.

Overdose Scope: Regulatory Findings Official Statement Summary
Manifestations No toxic effects are expected following an ocular overdose of the product.
Systemic Risk Systemic toxicity is not anticipated due to the preparation being pharmacologically inert and exhibiting negligible systemic absorption.
Ingestion Risk No toxic effects are expected even after accidental ingestion of the entire contents of one bottle.
Required Action If the product is swallowed, seek medical help or contact a poison control center right away.

The overall overdose profile is established by the high-level regulatory classification that the substance is not expected to result in any toxic systemic effects. This finding is consistent across authoritative governmental documents and is directly linked to the active ingredient’s inert nature. Despite this non-toxic classification, the official labeling dictates a mandatory emergency response statement: immediate medical attention is required if the solution is accidentally swallowed. In such situations, the management described is symptomatic and supportive, reflecting the need for general care rather than intervention for specific systemic poisoning. No population-specific overdose considerations are documented in the official regulatory sections.

Therapeutic Uses of Luvis

What Luvis Treats: Main Uses and Benefits

Luvis (Hypromellose) is an ophthalmic solution primarily used to provide supportive symptomatic relief for conditions presenting with symptoms of dryness and reduced surface moisture. The product is used to help manage symptoms related to dryness and to support the eye surface. Its application is relevant across domains where short-term symptomatic assistance is appropriate.


Therapeutic Scope and Patient Benefit

Luvis is relevant in conditions characterized by periods of heightened symptoms, such as Dry Eye Disease (DED) or Keratoconjunctivitis Sicca (KCS). It is typically applied to manage the persistent, mild to moderate symptoms associated with insufficient ocular moisture. The primary therapeutic focus is managing symptoms related to physical discomfort, such as ocular irritation, dryness, and foreign body sensation (FBS). This provides support that helps ease the overall symptom load during symptomatic periods, supporting patients during episodes of heightened discomfort, such as older adults or those with recurrent manifestations.


Quick Fact: Applicable Symptoms and Contexts
Luvis is commonly used across conditions presenting with acute or recurrent episodes of surface dryness, irritation, burning, and grittiness.

Regulatory References

  1. NIH DailyMed label overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Luvis?

The official eligibility profile for Luvis (Hypromellose ophthalmic solution) is primarily governed by the drug's nature as a non-systemic, inert agent, resulting in minimal absolute contraindications tied to systemic disease.


Populations for Whom Use is Contraindicated

Luvis must not be used by individuals with a known hypersensitivity or allergy to the active substance, Hypromellose, or to any of the inactive ingredients (excipients) in the specific formulation. Use is also restricted while wearing soft contact lenses if the product contains certain preservatives, which can be absorbed by the lens.

Age and Condition-Based Eligibility

The product is generally allowed for use in Adults and the Elderly. Although some regulatory documents state the dosage applies to children and infants, other official labels indicate that safety and efficacy in children and adolescents under 18 years are not established. Due to the product's negligible systemic absorption, no specific restrictions or dose adjustments are required for patients with renal (kidney) or hepatic (liver) impairment.

Pregnancy and Lactation

Use of Luvis is officially considered allowed during both pregnancy and breastfeeding. Regulatory safety evaluations anticipate no effects on the fetus or breastfed infant, a status based on the negligible systemic exposure to the mother.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Luvis (Hypromellose) is an ophthalmic lubricant that acts locally on the eye surface, and the entire interaction profile is structured around its pharmacologically inert nature and negligible systemic absorption, as documented in government regulatory sources.

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions: Other topical ophthalmic products, including eye drops (solutions) and ophthalmic ointments/gels.
Specific interacting medicines (if explicitly listed): None are specifically listed by name; the interaction applies to the entire class of other ocular medications.
Mechanistic basis of interactions (only if stated in label): Local Physico-Pharmacodynamic Interaction—the viscous nature of Hypromellose can interfere with the retention and contact time of other drugs on the ocular surface.
Timing-based interaction rules (if applicable): Mandatory temporal separation is required. Other eye drops must be administered at least five minutes apart from Luvis.

Interaction Classifications (High-Level)

Category Official Regulatory Information
Interaction severity classification (as defined in official documents): Not formally classified as "Contraindicated," but represents a required precautionary administration condition to ensure product efficacy.
Regulatory basis (EMA / FDA / etc.): Information is consistently presented across multiple government regulatory sources, including the European Summary of Product Characteristics (SmPC) and FDA Prescribing Information.
Interaction-context constraints (as defined in official documents): The constraints apply only when Luvis is used concurrently with any other medicine applied to the eye.

Resulting Interaction Structure

Official interaction statements:

  • No metabolic (CYP-mediated), systemic pharmacokinetic, or systemic pharmacodynamic interactions are documented due to the lack of significant systemic absorption.
  • The administration of Luvis alongside other ophthalmic solutions or ointments requires a minimum time interval of five minutes between applications.
  • This timing rule constitutes the sole interaction-related restriction documented in government regulatory sources.

Regulatory documents define the product's interaction structure primarily through its inert profile and non-systemic route of administration, which eliminates the potential for metabolic or systemic drug-drug interactions. Consequently, the entire official interaction profile is limited to a single precautionary timing constraint that is required to manage the physical retention of other ophthalmic products on the eye surface.

Mechanism of Action

Luvis functions by engaging specific physiological mechanisms, primarily within the ocular system, to induce localized and pharmacologically induced changes. The drug's action is defined by its selective influence on certain signaling pathways, leading to defined physiological changes.


Modulation of Cholinergic Receptors

Luvis acts within the domain of receptor-mediated signaling as a cholinergic muscarinic agonist. This mechanism involves activating muscarinic receptors on smooth muscles in the eye, namely the iris sphincter and the ciliary muscle. This initial molecular event triggers a signaling cascade that governs muscle contraction.


Induction of Pupillary and Ciliary Muscle Contraction

The key physiological consequence of the drug's mechanism is the induction of contraction in the targeted smooth muscles. This results in two primary, simultaneous effects: the constriction of the pupil (miosis) and the tightening of the ciliary muscle. This contraction alters the geometry within the eye's refractive structures.


Modification of Ocular Optical Characteristics

The cascade of receptor activation and subsequent muscle contraction leads to a physiological adjustment that modifies the optical characteristics of the eye. By reducing the pupil's diameter and modifying the shape of the lens via the ciliary muscle, the mechanism elicits physiological adjustments that define the drug’s action profile.

Dosage and Administration Information

How to Use Luvis

Luvis is administered exclusively as a 600 mg intravenous infusion (into a vein) by a qualified healthcare professional in a medical setting.


Official Dosing Schedule

Administration follows a precise, scheduled pattern designed to ensure correct use:

  • Initial Course: The first dose is administered, followed by the second dose exactly two weeks later.
  • Subsequent Doses: After the first two doses, all subsequent doses are administered every 24 weeks (approximately six months).

Preparation and Administration

Prior to administration, the medicine must undergo dilution before it can be infused intravenously. The entire dose is administered over a period as determined by your healthcare provider. This procedure ensures the drug is delivered correctly.

Missed Dose Instructions

If a scheduled infusion is missed, you must contact your healthcare provider immediately. The instructions state that the missed dose should be administered as soon as possible. The subsequent doses are then rescheduled to occur 24 weeks after the day the delayed infusion was given.


Administration Scope Detail
Route Intravenous Infusion (IV)
Dose 600 mg
Initial Frequency Two doses, 2 weeks apart
Maintenance Frequency Every 24 weeks

Recent Clinical Evidence

Luvis: Recent Clinical Evidence

Recent clinical trials have explored the therapeutic potential of Luvis (recombinant human Luteinizing Hormone or lutropin alfa) beyond its established use in assisted reproductive technology (ART), specifically for ovarian stimulation in women with pronounced Luteinizing Hormone (LH) deficiency.

Efficacy in Assisted Reproduction

Clinical data from randomized trials comparing different regimens for controlled ovarian stimulation in women undergoing In Vitro Fertilization (IVF) cycles has provided insights into Luvis dosing. Studies have evaluated the effect of recombinant LH in women with conditions that lead to low endogenous LH activity, such as hypothalamic amenorrhea. While Luvis is approved to be used in conjunction with Follicle Stimulating Hormone (FSH), trials have focused on determining optimal protocols, including fixed-dose versus increasing-dose regimens of Luvis, to potentially mimic the natural menstrual cycle and improve follicular response, oocyte quality, and overall pregnancy rates. These studies continue to refine clinical practice for the use of recombinant LH in specific patient populations within ART.

Area of Investigation Clinical Trial Findings
Dosing Regimen Exploration of fixed versus escalating Luvis doses with co-administered FSH to optimize follicular development.
Primary Endpoint Focus on the number of mature follicles (e.g., 16 mm) and midsize follicles (e.g., 12-16 mm) at the time of human Chorionic Gonadotropin (hCG) administration.

Safety Profile Observations

The overall safety profile of Luvis in IVF treatment remains consistent with previous findings for gonadotropins used in ART. The main safety considerations include injection site reactions and the general risks associated with ovarian stimulation, such as ovarian hyperstimulation syndrome (OHSS) and multiple pregnancy, which are monitored closely as part of the established treatment protocols.

It is important to note that the established clinical evidence for Luvis is primarily confined to its role in the treatment of specific female infertility conditions. Ongoing research seeks to further clarify the precise role of supplemental LH, such as Luvis, in various ART protocols to maximize treatment success.

Frequently Asked Questions (FAQ)

Common questions about Luvis (FAQ)

Q: Is it normal to feel a bit tired when starting Luvis?

Official product information does not list systemic effects like fatigue or tiredness as documented adverse reactions for the Luvis ophthalmic solution. The side effects described in regulatory documents are generally localized and confined to the eyes. This profile is consistent with the drug's mechanism as a topical eye lubricant with negligible systemic absorption.


Q: Does taking Luvis impact fertility or conception?

Studies to evaluate the effect of the ophthalmic solution on fertility have not been performed according to official product information. However, due to its inert nature and minimal systemic absorption, official safety evaluations indicate that systemic effects on reproductive processes are unlikely.


Q: Is there a recommended time of day to take Luvis?

Official instructions for Luvis specify the required frequency of use, such as the general recommended pattern for the ophthalmic solution. However, regulatory documents do not mandate a particular time of day, such as morning or evening, for the administration of the medicine.


Q: How long do the effects of Luvis last after the last dose?

Luvis works by physically enhancing the viscosity of the tear film, which prolongs its retention time on the eye's surface. Regulatory dosing instructions reflect this action, often indicating that the drops are administered as needed or several times a day to maintain the desired effect.


Q: Do I need a special prescription or monitoring program for Luvis?

The classification of Luvis depends on the formulation and market; the ophthalmic solution is commonly available over-the-counter (OTC). In contrast, the intravenous infusion is authorized only for administration by a qualified healthcare professional in a medical setting. Official documents indicate that professional monitoring may be suggested for prolonged use of the ophthalmic solution.


Q: What is Luvis used for besides its main purpose?

According to official product indications, Luvis is primarily used to relieve symptoms of dryness. Additionally, regulatory documents state it is indicated as an artificial tear to prevent corneal damage in certain eye conditions, and to lubricate both hard contact lenses and artificial eyes.


Q: How quickly does Luvis start to work after you take it?

Since Luvis functions as a physical lubricant on the eye's surface, its action is considered immediate. Official labeling notes that certain transient effects, such as brief blurred vision, can occur immediately upon instillation, indicating the rapid onset of its physical effect.


Q: What is the longest time Luvis can be used according to research?

Luvis is an ophthalmic lubricant used for the management of chronic conditions, and its regulatory profile is consistent with management of chronic conditions. Official information describes the active ingredient as an inert substance that is not associated with systemic toxicity, and no specific maximum treatment duration is defined.


Q: Are there any long-term effects of taking Luvis for several years?

Official regulatory evaluations describe the active ingredient, Hypromellose, as an inert compound with negligible systemic absorption and a low level of toxicity. This profile is consistent with its long-term use for reducing the signs and symptoms of dry eye disease.


Q: Is there a generic version of Luvis available?

Yes, regulatory and drug information sources confirm that the active substance in Luvis is available as a generic product in many markets.


Q: If I feel better, can I stop taking Luvis?

Official regulatory information indicates the product is administered based on the need for symptomatic relief. Patient information describes the conditions for stopping use if irritation persists or worsens, and notes that consultation with a professional may be necessary if irritation persists.


Q: What should I tell my doctor about before starting Luvis?

The official patient leaflet contains information regarding when consultation may be relevant. This includes if eye irritation continues or worsens, or if new symptoms, such as headache, eye pain, vision changes, or continued redness, develop.


Q: Does the dosage of Luvis change based on body weight?

The dose recommendations specified in regulatory documents are generally described as a fixed volume for the ophthalmic solution. Official information for both adults and the elderly makes no mention of dosage adjustments based on body weight.


Q: What kind of monitoring is needed while taking Luvis?

Official documents indicate that professional monitoring may be necessary for patients who use the ophthalmic solution for a prolonged period. This precaution is particularly noted if the formulation contains certain preservatives, or if the user experiences persistent irritation.


Q: What is the difference between the brand name and the generic equivalent of Luvis?

Regulatory documents specify that while generic products contain the same active ingredient as the brand name, differences often exist in the inactive ingredients, also known as excipients. These differences typically relate to the formulation's physical characteristics or appearance.

How should Luvis be stored and disposed of?

The official storage and disposal guidelines for Luvis (Hypromellose) are mandatory to maintain product stability and ensure safety, as directed by regulatory authorities.

Storage Requirements

Condition Official Rule (As Stated in Labeling)
Temperature Store at controlled room temperature (15C to 30C or not above 25C). Do not freeze.
Protection Keep the solution in its original package, protected from direct light and moisture.
Container Integrity The cap must be tightly closed immediately after use. Do not use if the solution changes color or becomes cloudy.
Child Safety Mandatory requirement: Keep out of the sight and reach of children.

Disposal and Stability

The product's shelf-life is strictly limited once opened. The contents of the bottle must be discarded 28 days after the first opening, even if solution remains. When disposing of the medicine, regulatory instructions state that it must not be thrown away via wastewater or household waste. Patients are officially instructed to consult a pharmacist for guidance on proper disposal of any unused or expired solution.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Luvis found in:

A-Z Index: